Table 1.
Patient demographics and clinical characteristics by tumor location and regional emphysema score
| Regional emphysema score | group 1
|
group 2
|
group 3
|
|||||
|---|---|---|---|---|---|---|---|---|
| mild | moderate | severe | mild | moderate | severe | mild | moderate/severe | |
| Number of patients | 356 (63.0%) | 150 (26.6%) | 59 (10.4%) | 312 (71.7%) | 86 (19.8%) | 37 (8.5%) | 37 (50.7%) | 36 (49.3%) |
| Age (years) | 67.6±9.6 | 68.6±7.7 | 68.2±8.0 | 66.8±10.1 | 69.4±7.2 | 71.5±7.1** | 72.1±8.2 | 71.3±7.9 |
| Gender | ||||||||
| Male | 176 (49.4%) | 98 (65.3%) | 35 (59.3%)* | 147 (47.1%) | 56 (65.1%) | 19 (51.4%)* | 19 (51.4%) | 17 (47.2%) |
| Female | 180 (50.6%) | 52 (34.7%) | 24 (40.7%) | 165 (52.9%) | 30 (34.9%) | 18 (48.6%) | 18 (48.6%) | 19 (52.8%) |
| Body mass index | 27.8±5.0 | 26.5±4.6 | 25.0±5.0** | 28.4±5.7 | 26.4±4.7 | 25.5±4.4** | 28.6±5.6 | 26.6±5.5 |
| Smoking status | ||||||||
| Never | 63 (17.7%) | 1 (0.7%) | 0 (0.0%)** | 77 (24.7%) | 2 (2.3%) | 0 (0.0%)** | 5 (13.5%) | 0 (0.0%)* |
| Former | 207 (58.1%) | 80 (53.3%) | 35 (59.3%) | 177 (56.7%) | 57 (66.3%) | 27 (73.0%) | 26 (70.3%) | 25 (69.4%) |
| Current/ever | 86 (24.2%) | 69 (46.0%) | 24 (40.7%) | 58 (18.6%) | 27 (31.4%) | 10 (27.0%) | 6 (16.2%) | 11 (30.6%) |
| Pack-years | 46.0±31.1 | 59.5±32.2 | 66.6±33.0** | 45.0±31.4 | 58.1±27.4 | 52.8±27.6** | 50.6±39.8 | 65.4±33.4* |
| Histology | ||||||||
| adenocarcinoma | 240 (67.4%) | 84 (56.0%) | 22 (37.3%)** | 181 (58.0%) | 42 (48.8%) | 18 (48.6%)** | 16 (43.2%) | 11 (30.6%) |
| squamous | 79 (22.2%) | 55 (36.7%) | 28 (47.5%) | 59 (18.9%) | 36 (41.9%) | 13 (35.1%) | 13 (35.1%) | 15 (41.7%) |
| other NSCLC | 37 (10.4%) | 11 (7.3%) | 9 (15.3%) | 72 (23.1%) | 8 (9.3%) | 6 (16.2%) | 8 (21.6%) | 10 (27.8%) |
| Grade | ||||||||
| well | 138 (38.8%) | 35 (23.3%) | 8 (13.6%)** | 112 (35.9%) | 21 (24.4%) | 6 (16.2%)** | 7 (18.9%) | 4 (11.1%) |
| moderate | 152 (42.7%) | 86 (57.3%) | 31 (52.5%) | 113 (36.2%) | 53 (61.6%) | 23 (62.2%) | 14 (37.8%) | 15 (41.7%) |
| poorly | 66 (18.5%) | 29 (19.3%) | 20 (33.9%) | 87 (27.9%) | 12 (14.0%) | 8 (21.6%) | 16 (43.2%) | 17 (47.2%) |
| Stage | ||||||||
| Ia | 208 (58.4%) | 70 (46.7%) | 25 (42.4%)** | 160 (51.3%) | 39 (45.3%) | 24 (64.9%) | 11 (29.7%) | 13 (36.1%) |
| Ib | 88 (24.7%) | 44 (29.3%) | 14 (23.7%) | 73 (23.4%) | 21 (24.4%) | 9 (24.3%) | 6 (16.2%) | 8 (22.2%) |
| IIa | 26 (7.3%) | 19 (12.7%) | 6 (10.2%) | 46 (14.7%) | 13 (15.1%) | 3 (8.1%) | 4 (10.8%) | 3 (8.3%) |
| IIb | 34 (9.6%) | 17 (11.3%) | 14 (23.7%) | 33 (10.6%) | 13 (15.1%) | 1 (2.7%) | 16 (43.2%) | 12 (33.3%) |
| Comorbid COPD | ||||||||
| no | 206 (57.9%) | 33 (22.0%) | 5 (8.5%)** | 181 (58.0%) | 16 (18.6%) | 4 (10.8%)** | 13 (35.1%) | 2 (5.6%)** |
| yes | 150 (42.1%) | 117 (78.0%) | 54 (91.5%) | 131 (42.0%) | 70 (81.4%) | 33 (89.2%) | 24 (64.9%) | 34 (94.4%) |
Comparisons between different emphysema scores in three comparative groups:
*
p<0.05,
**
p<0.01
NSCLC, non-small cell lung cancer; COPD, chronic obstructive pulmonary disease.